单中心开放标签研究:成人皮内接种灭活纯化鸡胚细胞培养狂犬病病毒疫苗
该单中心开放标签试验将130名成人志愿者分为皮内暴露前预防、肌内暴露前预防、皮内加强和肌内加强四组,比较纯化鸡胚细胞狂犬病疫苗皮内与肌内接种的免疫原性和不良反应。接种后14-21天两组抗体滴度上升速率相似,皮内组GMT略低于对应肌内组且差异有统计学意义;完成接种后14天所有人中和抗体均超过RFFIT最低任意值并持续至试验结束(完成后160天),未报告严重不良反应。
要点
- 皮内组与对应肌内组接种后14-21天狂犬病病毒中和抗体滴度上升速率相似。
- 皮内组GMT略低于对应肌内组, naïve组和加强组差异经t检验均有统计学意义。
- 完成接种后14天全部受试者中和抗体超过RFFIT最低任意值并维持至完成后160天。
核心结论
- 皮内接种0.1mL纯化鸡胚细胞狂犬病疫苗与肌内接种1mL在抗体上升速率上相似,皮内组GMT略低但所有受试者抗体均超过设定阈值,且未报告严重不良反应。
- 1mL狂犬病疫苗瓶多剂量用于0.1mL皮内接种被证明安全且有免疫原性。
研究设计与样本
- 单中心开放标签临床试验,入组130名成人志愿者,设皮内暴露前预防、肌内暴露前预防、皮内加强和肌内加强四组。
- 肌内组按当前ACIP建议接种:暴露前预防于第0、7、21天各接种1mL(2.5 I.U.);或常规加强接种1mL一剂。
- 皮内组采用相同程序,但接种体积为0.1mL(0.25 I.U.)。
主要发现
- 接种后14-21天狂犬病病毒中和抗体滴度上升速率在皮内组与对应肌内组相似。
- 皮内组GMT值略低于对应肌内组, naïve组和加强组差异经t检验均有统计学意义。
- 完成接种后14天全部受试者中和抗体滴度超过RFFIT获得的最低任意值,并持续至试验结束即完成接种后160天。
- 未报告严重不良反应;最常见不良反应为注射部位红斑、硬结和压痛。
关键数值与推荐
- 肌内暴露前预防:第0、7、21天各1mL(2.5 I.U.)狂犬病疫苗。
- 皮内接种:相同程序,体积0.1mL(0.25 I.U.)。
- 肌内加强:1mL一剂;皮内加强:0.1mL一剂。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the USA, rabies vaccines (RVs) are licensed for intramuscular (IM) use only, although RVs are licensed for use by the intradermal (ID) route in many other countries. Recent limitations in supplies of RV in the USA reopened discussions on the more efficient use of available biologics, including utilization of more stringent risk assessments, and potential ID RV administration. A clinical trial was designed to compare the immunogenic and adverse effects of a purified chicken embryo cell (PCEC) RV administered ID or IM. Enrollment was designed in four arms, ID Pre-Exposure Prophylaxis (Pre-EP), IM Pre-EP, ID Booster, and IM Booster vaccination. Enrollment included 130 adult volunteers. The arms with IM administration received vaccine according to the current ACIP recommendations: Pre-EP, three 1mL (2.5 I.U.) RV doses, each on day 0, 7, and 21; or a routine Booster, one 1ml dose. The ID groups received the same schedule, but doses administered were in a volume of 0.1mL (0.25 I.U.). The rate of increase in rabies virus neutralizing antibody titers 14-21days after vaccination were similar in the ID and correspondent IM groups. The GMT values for ID vaccination were slightly lower than those for IM vaccination, for both naïve and booster groups, and these differences were statistically significant by t-test. Fourteen days after completing vaccination, all individuals developed RV neutralizing antibody titers over the minimum arbitrary value obtained with the rapid fluorescent focus inhibition test (RFFIT). Antibodies were over the set threshold until the end of the trial, 160days after completed vaccination. No serious adverse reactions were reported. Most frequent adverse reactions were erythema, induration and tenderness, localized at the site of injection. Multi use of 1mL rabies vaccine vials for ID doses of 0.1 was demonstrated to be both safe and inmunogenic.
引用
- Recuenco S, Warnock E, Osinubi MOV, et al. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults. Vaccine. 2017. PMID: 28688782. doi:10.1016/j.vaccine.2017.06.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。